高海拔地区肺部非感染性疾病的研究新进展

doi:10.12114/j.issn.1007-9572.2024.0545

摘要/Abstract

摘要： 高海拔地区具有低温、低湿、低压和低氧等特征，这些特征可引发一系列生理反应，显著影响肺部健康。本文全面总结了高海拔地区特殊环境对急、慢性肺部非感染性疾病的影响，分析了发病率、发病机制、临床指标及预后等因素。高海拔地区环境对急性疾病，如高原肺水肿（HAPE）和肺栓塞（PE），以及对其他慢性疾病如慢性阻塞性肺疾病（COPD）、慢性肺源性心脏病（CPHD）、哮喘、高原性肺动脉高压（HAPH）、肺纤维化（PF）、阻塞性睡眠呼吸暂停综合征（OSAS）和肺癌等疾病的影响，并与低海拔地区进行影响因素对比分析，旨在综述高海拔地区环境对肺组织损伤的机制，并分析其与各种肺部非感染性疾病的关系，以期为高海拔地区患者的肺部非感染性疾病的诊断和治疗提供针对性指导。

关键词: 高海拔, 肺疾病, 非感染性疾病, 慢性阻塞性肺疾病, 哮喘, 高原肺水肿

Abstract:

High-altitude areas are characterized by hypothermia, low humidity, hypobaric and hypoxia, which may trigger a series of physiological responses that significantly affect lung health. This article made a comprehensive summary of the impact of unique environment in high-altitude areas on acute and chronic non-infectious lung diseases. And these factors of the morbidity, pathogenesis, clinical data and prognosis were analyzed. The environmental conditions of high-altitude areas affected acute diseases, such as high-altitude pulmonary edema (HAPE) and pulmonary embolism (PE), as well as chronic diseases like chronic obstructive pulmonary disease (COPD), chronic pulmonary heart disease (CPHD), asthma, high-altitude pulmonary hypertension (HAPH), pulmonary fibrosis (PF), obstructive sleep apnea syndrome (OSAS), and lung cancer. A comparative analysis of the influencing factors between high-altitude and low-altitude areas was conducted, aiming to review the mechanisms of lung tissue damage in high-altitude environments and to analyze its relationship with different non-infectious pulmonary diseases. It aimed to provide targeted guidance for the diagnosis and treatment of non-infectious pulmonary diseases in high-altitude areas.

Key words: High altitude, Lung diseases, Non-communicable diseases, Chronic obstructive pulmonary disease, Asthma, High altitude pulmonary edema

中图分类号:

R 563

赵雪丹,艾悦,靳国恩,等. 高海拔地区肺部非感染性疾病的研究新进展[J]. 中国全科医学, 2026, 29(14): 1931-1938. DOI: 10.12114/j.issn.1007-9572.2024.0545.
ZHAO Xuedan,AI Yue,JIN Guoen, et al. The New Research Progress of Non-infectious Lung Diseases in High Altitude Areas[J]. Chinese General Practice, 2026, 29(14): 1931-1938. DOI: 10.12114/j.issn.1007-9572.2024.0545.

图/表 1

参考文献 78

[1]	TREMBLAY J C, AINSLIE P N. Global and country-level estimates of human population at high altitude[J]. Proc Natl Acad Sci USA, 2021, 118(18): e2102463118. DOI: 10.1073/pnas.2102463118.
[2]	AKSEL G, ÇORBACıOĞLU Ş K, ÖZEN C. High-altitude illness: management approach[J]. Turk J Emerg Med, 2019, 19(4): 121-126. DOI: 10.1016/j.tjem.2019.09.002.
[3]	PENA E, BRITO J, EL ALAM S, et al. Oxidative stress, kinase activity and inflammatory implications in right ventricular hypertrophy and heart failure under hypobaric hypoxia[J]. Int J Mol Sci, 2020, 21(17): 6421. DOI: 10.3390/ijms21176421.
[4]	扎西曲宗, 格桑罗布, 次白, 等. 高原病药物预防及治疗的研究现状[J]. 中国临床药理学杂志, 2024, 40(11): 1689-1692. DOI: 10.13699/j.cnki.1001-6821.2024.11.032.
[5]	GUDBJARTSSON T, SIGURDSSON E, GOTTFREDSSON M, et al. High altitude illness and related diseases - a review[J]. Laeknabladid, 2019, 105(11): 499-507. DOI: 10.17992/lbl.2019.11.257.
[6]	ZUBIETA-CALLEJA G, ZUBIETA-DEURIOSTE N. The oxygen transport triad in high-altitude pulmonary edema: a perspective from the high Andes[J]. Int J Environ Res Public Health, 2021, 18(14): 7619. DOI: 10.3390/ijerph18147619.
[7]	SAVIOLI G, CERESA I F, GORI G, et al. Pathophysiology and therapy of high-altitude sickness: practical approach in emergency and critical care[J]. J Clin Med, 2022, 11(14): 3937. DOI: 10.3390/jcm11143937.
[8]	PICHLER HEFTI J, JEAN D, ROSIER A J, et al. High-altitude pulmonary edema in women: a scoping review-UIAA medical commission recommendations[J]. High Alt Med Biol, 2023, 24(4): 268-273. DOI: 10.1089/ham.2023.0054.
[9]	SWENSON E R. Early hours in the development of high-altitude pulmonary edema: time course and mechanisms[J]. J Appl Physiol, 2020, 128(6): 1539-1546. DOI: 10.1152/japplphysiol.00824.2019.
[10]	CHOI Y K. Detrimental roles of hypoxia-inducible factor-1α in severe hypoxic brain diseases[J]. Int J Mol Sci, 2024, 25(8): 4465. DOI: 10.3390/ijms25084465.
[11]	SHARMA S, SANDHIR R, GANJU L, et al. Unique mutations in mitochondrial DNA and associated pathways involved in high altitude pulmonary edema susceptibility in Indian lowlanders[J]. J Biomol Struct Dyn, 2023, 41(11): 5183-5198. DOI: 10.1080/07391102.2022.2081610.
[12]	KUSHWAHA A D, KALRA N, VARSHNEY R, et al. Mitochondrial Ca²⁺ overload due to altered proteostasis amplifies apoptosis in C2C12 myoblasts under hypoxia: Protective role of nanocurcumin formulation[J]. IUBMB Life, 2023, 75(8): 673-687. DOI: 10.1002/iub.2720.
[13]	ZHAO Y C, XIONG W D, LI C F, et al. Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets[J]. Signal Transduct Target Ther, 2023, 8(1): 431. DOI: 10.1038/s41392-023-01652-9.
[14]	RUAN H, ZHANG Q, ZHANG Y P, et al. Unraveling the role of HIF-1α in sepsis: from pathophysiology to potential therapeutics-a narrative review[J]. Crit Care, 2024, 28(1): 100. DOI: 10.1186/s13054-024-04885-4.
[15]	EICHSTAEDT C A, BENJAMIN N, CAO D, et al. Genetics of high-altitude pulmonary edema[J]. Heart Fail Clin, 2023, 19(1): 89-96. DOI: 10.1016/j.hfc.2022.07.002.
[16]	WU J L, HAN X B, KE H W, et al. Pulmonary embolism at extreme high altitude: a study of seven cases[J]. High Alt Med Biol, 2022, 23(3): 209-214. DOI: 10.1089/ham.2021.0109.
[17]	李兰, 程文栋, 黄东霞, 等.高原地区慢阻肺患者合并症及病原学的研究进展[J]. 吉林医药学院学报, 2025, 46(2): 130-134. DOI: 10.13845/j.cnki.issn1673-2995.20240722.002.
[18]	LU X T, LI Y, WANG Z P, et al. Clinical characteristics of patients with acute pulmonary embolism in high altitude area of Yunnan province in China[J]. Zhonghua Xin Xue Guan Bing Za Zhi, 2022, 50(1): 36-42. DOI: 10.3760/cma.j.cn112148-20211203-01045.
[19]	YANG C L, TUO Y J, SHI X F, et al. Prevalence, risk factors, and clinical characteristics of pulmonary embolism in patients with acute exacerbation of COPD in Plateau regions: a prospective cohort study[J]. BMC Pulm Med, 2024, 24(1): 102. DOI: 10.1186/s12890-024-02915-z.
[20]	QIAN Z, FAN A L, DA W, et al. Retrospective cohort analysis of heart rate variability in patients with high altitude pulmonary hypertension in Tibet[J]. Clin Cardiol, 2020, 43(3): 298-304. DOI: 10.1002/clc.23312.
[21]	NAEIJE R. High altitude travelling with pulmonary arterial hypertension[J]. Eur Respir J, 2024, 63(3): 2400111. DOI: 10.1183/13993003.00111-2024.
[22]	LIU J N, ZHAO Z G, LUO F M. Pulmonary hypertension-related dynamic left ventricular outflow tract obstruction[J]. Eur Heart J, 2023, 44(45): 4814. DOI: 10.1093/eurheartj/ehad605.
[23]	FLORES K, SIQUES P, BRITO J, et al. AMPK and the challenge of treating hypoxic pulmonary hypertension[J]. Int J Mol Sci, 2022, 23(11): 6205. DOI: 10.3390/ijms23116205.
[24]	WANG C, XU J Y, YANG L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health [CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717. DOI: 10.1016/S0140-6736(18)30841-9.
[25]	陈瑜婷, 黄玲, 夏俊杰, 等. 中国高原地区慢性阻塞性肺疾病患病率及危险因素Meta分析[J]. 华西医学, 2023, 38(7): 1058-1064.
[26]	GUO Y F, XING Z Z, SHAN G L, et al. Prevalence and risk factors for COPD at high altitude: a large cross-sectional survey of subjects living between 2 100-4 700 m above sea level[J]. Front Med, 2020, 7: 581763. DOI: 10.3389/fmed.2020.581763.
[27]	XIONG H Y, HUANG Q R, HE C Y, et al. Prevalence of chronic obstructive pulmonary disease at high altitude: a systematic review and meta-analysis[J]. PeerJ, 2020, 8: e8586. DOI: 10.7717/peerj.8586.
[28]	LIN A, MAO C, RAO B Q, et al. Development and validation of nomogram including high altitude as a risk factor for COPD: a cross-sectional study based on Gansu population[J]. Front Public Health, 2023, 11: 1127566. DOI: 10.3389/fpubh.2023.1127566.
[29]	JO Y S. Long-term outcome of chronic obstructive pulmonary disease: a review[J]. Tuberc Respir Dis, 2022, 85(4): 289-301. DOI: 10.4046/trd.2022.0074.
[30]	曾祥海, 索南格勒, 黄琴, 等. 高原环境影响慢性阻塞性肺疾病及治疗药物的研究进展[J]. 生理学报, 2023, 75(5): 691-702. DOI: 10.13294/j.aps.2023.0066.
[31]	LIANG Y, YANGZOM D, TSOKYI L, et al. Clinical and radiological features of COPD patients living at ≥3000 m above sea level in the Tibet Plateau[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16: 2445-2454. DOI: 10.2147/COPD.S325097.
[32]	王士伟, 康龙丽. 动脉型肺动脉高压治疗研究进展[J]. 中山大学学报:医学科学版, 2024, 45(4): 493-502. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20240617.008.
[33]	LICHTBLAU M, SAXER S, FURIAN M, et al. Cardiac function and pulmonary hypertension in Central Asian highlanders at 3250 m[J]. Eur Respir J, 2020, 56(2): 1902474. DOI: 10.1183/13993003.02474-2019.
[34]	GOU Q L, SHI R F, ZHANG X, et al. The prevalence and risk factors of high-altitude pulmonary hypertension among native tibetans in Sichuan Province, China[J]. High Alt Med Biol, 2020, 21(4): 327-335. DOI: 10.1089/ham.2020.0022.
[35]	HOYOS R, LICHTBLAU M, CAJAMARCA E, et al. Characteristics and risk profiles of patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension living permanently at >2500 m of high altitude in Ecuador[J]. Pulm Circ, 2024, 14(3): e12404. DOI: 10.1002/pul2.12404.
[36]	EICHSTAEDT C A, BENJAMIN N, GRÜNIG E. Genetics of pulmonary hypertension and high-altitude pulmonary edema[J]. J Appl Physiol, 2020, 128(5): 1432-1438. DOI: 10.1152/japplphysiol.00113.2020.
[37]	TAIMEH Z. Assessment and treatment of the failing right heart: considerations for transplantation referral[J]. J Thorac Dis, 2019, 11(Suppl 14): S1817-S1820. DOI: 10.21037/jtd.2019.08.60.
[38]	MIRRAKHIMOV A E, STROHL K P. High-altitude pulmonary hypertension: an update on disease pathogenesis and management[J]. Open Cardiovasc Med J, 2016, 10: 19-27. DOI: 10.2174/1874192401610010019.
[39]	叶祥琳, 古丽胡玛, 岳娇, 等. 高原肺动脉高压的发病机制与药物治疗研究进展[J]. 暨南大学学报(自然科学与医学版), 2022, 43(5): 467-479. DOI: 10.11778/j.jdxb.20220215.
[40]	万钧, 翟振国. 肺动脉高压临床诊治和管理中需要关注的热点问题——基于《2022ESC/ERS肺动脉高压诊治指南》与《中国肺动脉高压诊断与治疗指南(2021版)》的比较与解读[J]. 中国全科医学, 2023, 26(3): 255-261, 267. DOI: 10.12114/j.issn.1007-9572.2022.0692.
[41]	鲜海英, 何清华. 高原地区COPD合并肺心病的风险因素及其与血清hs-CRP、NT-proBNP、TNF-α的关系[J]. 川北医学院学报, 2024, 39(1): 63-66, 83. DOI: 10.3969/j.issn.1005-3697.2024.01.015.
[42]	SUN Y Q, MA J F, YAN T J, et al. Evaluation of cardiac index and right ventricular hypertrophy index in rats under a chronic hypoxic environment at high altitude[J]. Heliyon, 2024, 10(3): e25229. DOI: 10.1016/j.heliyon.2024.e25229.
[43]	FENG X K, YANG C L, SUN Z R, et al. Risk factors for mortality in patients with acute exacerbation of cor pulmonale in plateau[J]. BMC Pulm Med, 2023, 23(1): 238. DOI: 10.1186/s12890-023-02509-1.
[44]	CALDERÓN-GERSTEIN W, BRUNO-HUAMÁN A, DAMIÁN-MUCHA M, et al. Predictive capacity of the brain natriuretic peptide in the screening of heart failure in a high altitude population[J]. Respir Physiol Neurobiol, 2021, 289: 103654. DOI: 10.1016/j.resp.2021.103654.
[45]	ZHENG C Y, WANG X, TANG H S, et al. Habitation altitude and left ventricular diastolic function: a population-based study[J]. J Am Heart Assoc, 2021, 10(3): e018079. DOI: 10.1161/JAHA.120.018079.
[46]	BUSH A, PAVORD I D. Forthcoming UK asthma guidelines: an opportunity to improve asthma outcomes[J]. Lancet, 2021, 398(10314): 1856-1858. DOI: 10.1016/S0140-6736(21)02244-3.
[47]	MENDY A, MERSHA T B. Comorbidities in childhood-onset and adult-onset asthma[J]. Ann Allergy Asthma Immunol, 2022, 129(3): 327-334. DOI: 10.1016/j.anai.2022.05.005.
[48]	OCHOA-AVILÉS C, MORILLO D, RODRIGUEZ A, et al. Prevalence and risk factors for asthma, rhinitis, eczema, and atopy among preschool children in an Andean city[J]. PLoS One, 2020, 15(7): e0234633. DOI: 10.1371/journal.pone.0234633.
[49]	XING Z Z, YANG T, SHI S, et al. Ambient particulate matter associates with asthma in high altitude region: a population-based study[J]. World Allergy Organ J, 2023, 16(5): 100774. DOI: 10.1016/j.waojou.2023.100774.
[50]	NING Z X, HE S Z, LIU Q S, et al. Effects of the interaction between cold spells and fine particulate matter on mortality risk in Xining: a case-crossover study at high altitude[J]. Front Public Health, 2024, 12: 1414945. DOI: 10.3389/fpubh.2024.1414945.
[51]	LI Y F, FRANDSEN K M, GUO W Q, et al. Impact of altitude on the dosage of indoor particulates entering an individual's small airways[J]. J Hazard Mater, 2024, 468: 133856.
[52]	林红卫, 李王平, 金发光. PM2.5激活HIF-1α/NF-κB/VEGF通路对肺损伤的影响[J]. 中华肺部疾病杂志(电子版), 2022, 15(3): 316-322. DOI: 10.3877/cma.j.issn.1674-6902.2022.03.006.
[53]	SAXER S, BADER P R, SCHNEIDER S R, et al. Echocardiography and extravascular lung water during 3 weeks of exposure to high altitude in otherwise healthy asthmatics[J]. Front Physiol, 2023, 14: 1214887. DOI: 10.3389/fphys.2023.1214887.
[54]	FIETEN K B, RIJSSENBEEK-NOUWENS L H, HASHIMOTO S, et al. Less exacerbations and sustained asthma control 12 months after high altitude climate treatment for severe asthma[J]. Allergy, 2019, 74(3): 628-630. DOI: 10.1111/all.13664.
[55]	CHU M, GAO H L, ESPARZA P, et al. Chronic developmental hypoxia alters rat lung immune cell transcriptomes during allergic airway inflammation[J]. Physiol Rep, 2023, 11(3): e15600.
[56]	QUIGNON P, DA MATA P, FARAJ F, et al. Altitude healing effect in severe asthmatic children[J]. Respir Med Res, 2021, 79: 100810.
[57]	HOLTHOF K, BRIDEVAUX P O, FRÉSARD I. Underlying lung disease and exposure to terrestrial moderate and high altitude: personalised risk assessment[J]. BMC Pulm Med, 2022, 22(1): 187. DOI: 10.1186/s12890-022-01979-z.
[58]	白峻虎, 颜有霞, 杨丛珊, 等. 高原地区COPD合并肺间质纤维化的HRCT研究[J]. 高原医学杂志, 2016, 26(1): 53-55.
[59]	杨春艳, 付义, 陈冰, 等. 基于滇龙血竭的特发性肺间质纤维化分期论治方案构建及应用[EB/OL].[2024-10-04].
[60]	GUO B X, ZHANG Y, SUN X Y, et al. Convergent evolution in high-altitude and marine mammals: Molecular adaptations to pulmonary fibrosis and hypoxia[J]. Zool Res, 2024, 45(6): 1209-1220.
[61]	EL-HORANY H E, ATEF M M, ABDEL GHAFAR M T, et al. Empagliflozin ameliorates bleomycin-induced pulmonary fibrosis in rats by modulating Sesn2/AMPK/Nrf2 signaling and targeting ferroptosis and autophagy[J]. Int J Mol Sci, 2023, 24(11): 9481. DOI: 10.3390/ijms24119481.
[62]	王胜和, 雷延成. 高海拔地区肺间质性疾病的高分辨率CT表现及临床分析[J]. 青海医药杂志, 2019, 49(12): 47-50.
[63]	WANG S J, MA H S, LI H Y, et al. Alternatively expressed transcripts analysis of non-small cell lung cancer cells under different hypoxic microenvironment[J]. J Oncol, 2021, 2021: 5558304. DOI: 10.1155/2021/5558304.
[64]	SHI Y L, FAN S Q, WU M G, et al. YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression[J]. Nat Commun, 2019, 10(1): 4892. DOI: 10.1038/s41467-019-12801-6.
[65]	滕熠, 张晓丹, 夏昌发, 等. 中国与全球癌症发病、死亡和患病对比及其预测分析: GLOBOCAN 2022数据解读[J]. 中华肿瘤防治杂志, 2024, 31(23): 1413-1420.
[66]	KAUSHAL D, BAMOTRA S, YADAV S, et al. Particulate bound polycyclic aromatic hydrocarbons over Dhauladhar region of the north-western Himalayas[J]. Chemosphere, 2021, 263: 128298. DOI: 10.1016/j.chemosphere.2020.128298.
[67]	SIMEONOV K P, HIMMELSTEIN D S. Lung cancer incidence decreases with elevation: evidence for oxygen as an inhaled carcinogen[J]. PeerJ, 2015, 3: e705. DOI: 10.7717/peerj.705.
[68]	次登罗布, 普布次仁. 西藏地区肿瘤疾病谱及相关因素分析[J]. 中华肺部疾病杂志(电子版), 2021, 14(6): 822-823.
[69]	LI M, CHEN R, JI B Y, et al. Contribution of XPD and XPF polymorphisms to susceptibility of non-small cell lung cancer in high-altitude areas[J]. Public Health Genomics, 2021, 24(3/4): 189-198. DOI: 10.1159/000512641.
[70]	苏小凤, 刘霖, 仲琳, 等. 中国阻塞性睡眠呼吸暂停综合征患病率的Meta分析[J]. 中国循证医学杂志, 2021, 21(10): 1187-1194.
[71]	WANG H H, LI X Y, LI J H, et al. Sleep, short-term memory, and mood states of volunteers with increasing altitude[J]. Front Psychiatry, 2022, 13: 952399. DOI: 10.3389/fpsyt.2022.952399.
[72]	胡明侠, 陈文影, 王预建, 等. 青藏高原军队官兵睡眠疾病调查分析[J]. 世界睡眠医学杂志, 2019, 6(11): 1514-1516.
[73]	王欢欢, 刘霖, 陈开兵, 等. 高原官兵睡眠障碍与认知障碍研究进展[J]. 解放军医学院学报, 2021, 42(5): 571-573, 583.
[74]	TAN L, LI T M, LEI F, et al. Longer apnea duration at low altitude in Tibetan and Han highlanders compared with Han lowlanders: a retrospective study[J]. J Sleep Res, 2020, 29(2): e12934. DOI: 10.1111/jsr.12934.
[75]	PATRICIAN A, ANHOLM J D, AINSLIE P N. A narrative review of periodic breathing during sleep at high altitude: From acclimatizing lowlanders to adapted highlanders[J]. J Physiol, 2024, 602(21): 5435-5448. DOI: 10.1113/JP285427.
[76]	LI T M, TAN L, FURIAN M, et al. Sex-specific difference in the effect of altitude on sleep and nocturnal breathing in young healthy volunteers[J]. J Clin Med, 2022, 11(10): 2869.
[77]	CHU A A, YU H M, YANG H, et al. Evaluation of right ventricular performance and impact of continuous positive airway pressure therapy in patients with obstructive sleep apnea living at high altitude[J]. Sci Rep, 2020, 10: 20186.
[78]	TURNBULL C D, PHAM L V. Smoothing out the peaks and valleys of high-altitude sleep apnea[J]. Chest, 2021, 160(2): 411-412.